Advanced search
1 file | 762.62 KB

Eradication of Helicobacter pylori and gastric cancer : a systematic review and meta-analysis of cohort studies

Author
Organization
Abstract
Background: Helicobacter pylori (H. pylori) is associated with an increased risk of gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma and a decreased risk of esophageal adenocarcinoma. We aimed to assess how eradication therapy for H. pylori influences the risk of developing these cancers. Methods: This was a systematic review and meta-analysis. We searched PubMed, Web of Science, Embase, and the Cochrane Library and selected articles that examined the risk of gastric cancer, MALT lymphoma, or esophageal cancer following eradication therapy, compared with a noneradicated control group. Results: Among 3629 articles that were considered, ninemet the inclusion criteria. Of these, eight cohort studies assessed gastric cancer while one randomized trial assessed esophageal cancer. Out of 12 899 successfully eradicated patients, 119 (0.9%) developed gastric cancer, compared with 208 (1.1%) out of 18 654 noneradicated patients. The pooled relative risk of gastric cancer in all eight studies was 0.46 (95% confidence interval [CI] = 0.32 to 0.66, I-2 = 32.3%) favoring eradication therapy. The four studies adjusting for time of follow-up and confounders showed a relative risk of 0.46 (95% CI = 0.29 to 0.72, I-2 = 44.4%). Conclusions: This systematic review and meta-analysis indicates that eradication therapy for H. pylori prevents gastric cancer. There was insufficient literature for meta-analysis of MALT lymphoma or esophageal cancer.
Keywords
:INTESTINAL METAPLASIA, RANDOMIZED-TRIAL, MALT LYMPHOMA, RISK, INFECTION, ATROPHY, REDUCE, MORTALITY, THERAPY, JAPAN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 762.62 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Doorakkers, Eva, Jesper Lagergren, Lars Engstrand, and Nele Brusselaers. 2016. “Eradication of Helicobacter Pylori and Gastric Cancer : a Systematic Review and Meta-analysis of Cohort Studies.” Jnci-journal of the National Cancer Institute 108 (9).
APA
Doorakkers, E., Lagergren, J., Engstrand, L., & Brusselaers, N. (2016). Eradication of Helicobacter pylori and gastric cancer : a systematic review and meta-analysis of cohort studies. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108(9).
Vancouver
1.
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and gastric cancer : a systematic review and meta-analysis of cohort studies. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2016;108(9).
MLA
Doorakkers, Eva, Jesper Lagergren, Lars Engstrand, et al. “Eradication of Helicobacter Pylori and Gastric Cancer : a Systematic Review and Meta-analysis of Cohort Studies.” JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 108.9 (2016): n. pag. Print.
@article{8548987,
  abstract     = {Background: Helicobacter pylori (H. pylori) is associated with an increased risk of gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma and a decreased risk of esophageal adenocarcinoma. We aimed to assess how eradication therapy for H. pylori influences the risk of developing these cancers. 
Methods: This was a systematic review and meta-analysis. We searched PubMed, Web of Science, Embase, and the Cochrane Library and selected articles that examined the risk of gastric cancer, MALT lymphoma, or esophageal cancer following eradication therapy, compared with a noneradicated control group. 
Results: Among 3629 articles that were considered, ninemet the inclusion criteria. Of these, eight cohort studies assessed gastric cancer while one randomized trial assessed esophageal cancer. Out of 12 899 successfully eradicated patients, 119 (0.9%) developed gastric cancer, compared with 208 (1.1%) out of 18 654 noneradicated patients. The pooled relative risk of gastric cancer in all eight studies was 0.46 (95% confidence interval [CI] = 0.32 to 0.66, I-2 = 32.3%) favoring eradication therapy. The four studies adjusting for time of follow-up and confounders showed a relative risk of 0.46 (95% CI = 0.29 to 0.72, I-2 = 44.4%). 
Conclusions: This systematic review and meta-analysis indicates that eradication therapy for H. pylori prevents gastric cancer. There was insufficient literature for meta-analysis of MALT lymphoma or esophageal cancer.},
  articleno    = {djw132},
  author       = {Doorakkers, Eva and Lagergren, Jesper and Engstrand, Lars and Brusselaers, Nele},
  issn         = {0027-8874},
  journal      = {JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE},
  keywords     = {:INTESTINAL METAPLASIA,RANDOMIZED-TRIAL,MALT LYMPHOMA,RISK,INFECTION,ATROPHY,REDUCE,MORTALITY,THERAPY,JAPAN},
  language     = {eng},
  number       = {9},
  pages        = {9},
  title        = {Eradication of Helicobacter pylori and gastric cancer : a systematic review and meta-analysis of cohort studies},
  url          = {http://dx.doi.org/10.1093/jnci/djw132},
  volume       = {108},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: